Demonstrates high cure rates and reduced anthracycline exposure in childhood APL, indicating effective treatment strategies.
= .043, respectively). These data demonstrate that extended use of ATRA coupled to a risk-adapted consolidation can achieve high cure rates in childhood APL and limit anthracycline exposure. The trial was registered at www.clinicaltrials.gov as EudractCT 2008-002311-40.
No takes yet. Share an insight, caveat, or question.
Testi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: